Recently, antibodies that block the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed death-1/programmed death-ligand-1 (PD-1/PD-L-1) immune checkpoints have highlighted the potential of strategies that target tumor-induced inhibition of T cells to induce clinically relevant tumor control [1]. This evidence concerns the gene CD274 and neoplasm.